| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 105 | 2024 | 389 | 22.640 |
Why?
|
| Infant | 63 | 2024 | 3105 | 2.440 |
Why?
|
| Child, Preschool | 55 | 2024 | 3661 | 2.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 2516 | 2.050 |
Why?
|
| N-Myc Proto-Oncogene Protein | 20 | 2023 | 38 | 1.920 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 155 | 1.770 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 3 | 2020 | 4 | 1.750 |
Why?
|
| Child | 61 | 2024 | 7065 | 1.730 |
Why?
|
| HIV Infections | 10 | 2022 | 827 | 1.510 |
Why?
|
| 3-Iodobenzylguanidine | 8 | 2022 | 20 | 1.410 |
Why?
|
| Cell Proliferation | 6 | 2024 | 1627 | 1.400 |
Why?
|
| Prognosis | 35 | 2024 | 3729 | 1.370 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 1347 | 1.290 |
Why?
|
| Gene Amplification | 10 | 2021 | 133 | 1.280 |
Why?
|
| Induction Chemotherapy | 5 | 2022 | 149 | 1.260 |
Why?
|
| Disease-Free Survival | 24 | 2023 | 1210 | 1.200 |
Why?
|
| Oncogene Proteins | 13 | 2015 | 61 | 1.130 |
Why?
|
| Humans | 121 | 2024 | 87949 | 1.130 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1511 | 1.080 |
Why?
|
| Neoplasms, Second Primary | 6 | 2024 | 258 | 1.040 |
Why?
|
| Neoplasm Staging | 24 | 2024 | 1967 | 1.030 |
Why?
|
| Antineoplastic Agents | 14 | 2024 | 2392 | 1.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2024 | 1239 | 0.980 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 85 | 0.910 |
Why?
|
| Pelvic Neoplasms | 3 | 2014 | 45 | 0.900 |
Why?
|
| 5-Methylcytosine | 3 | 2022 | 113 | 0.880 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 1397 | 0.870 |
Why?
|
| Methyltransferases | 1 | 2024 | 190 | 0.860 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2023 | 81 | 0.850 |
Why?
|
| Immunotherapy | 8 | 2021 | 655 | 0.830 |
Why?
|
| Nuclear Proteins | 13 | 2015 | 721 | 0.830 |
Why?
|
| Adolescent | 36 | 2024 | 9111 | 0.810 |
Why?
|
| HIV-1 | 3 | 2021 | 164 | 0.800 |
Why?
|
| Female | 62 | 2024 | 45399 | 0.790 |
Why?
|
| Cell Differentiation | 5 | 2024 | 1501 | 0.780 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 56 | 0.770 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 64 | 0.770 |
Why?
|
| Survival Rate | 15 | 2024 | 1877 | 0.740 |
Why?
|
| Electronic Health Records | 1 | 2024 | 339 | 0.730 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 2513 | 0.730 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 12 | 0.730 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.720 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 883 | 0.710 |
Why?
|
| DNA Methylation | 4 | 2022 | 650 | 0.700 |
Why?
|
| Infant, Newborn | 15 | 2024 | 2436 | 0.700 |
Why?
|
| Male | 51 | 2024 | 41697 | 0.690 |
Why?
|
| Stem Cell Transplantation | 8 | 2019 | 187 | 0.680 |
Why?
|
| Epigenomics | 1 | 2019 | 103 | 0.660 |
Why?
|
| Naphthyridines | 1 | 2019 | 27 | 0.660 |
Why?
|
| Chromosome Aberrations | 6 | 2020 | 389 | 0.650 |
Why?
|
| Follow-Up Studies | 13 | 2024 | 3650 | 0.630 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 165 | 0.610 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 696 | 0.600 |
Why?
|
| Risk Factors | 20 | 2024 | 5405 | 0.590 |
Why?
|
| Prednisone | 1 | 2017 | 258 | 0.580 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.570 |
Why?
|
| Palmitic Acid | 1 | 2016 | 27 | 0.570 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.570 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 354 | 0.550 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 1703 | 0.550 |
Why?
|
| Isotretinoin | 3 | 2021 | 23 | 0.540 |
Why?
|
| Medical Oncology | 3 | 2021 | 374 | 0.540 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 198 | 0.520 |
Why?
|
| Altruism | 1 | 2015 | 35 | 0.520 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 342 | 0.500 |
Why?
|
| Interleukin-2 | 4 | 2022 | 250 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 2316 | 0.490 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2017 | 82 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 278 | 0.460 |
Why?
|
| Genomics | 3 | 2021 | 740 | 0.450 |
Why?
|
| Radiation Injuries | 1 | 2014 | 160 | 0.450 |
Why?
|
| Risk Assessment | 11 | 2023 | 2274 | 0.430 |
Why?
|
| Cohort Studies | 13 | 2021 | 2802 | 0.430 |
Why?
|
| Salvage Therapy | 4 | 2021 | 235 | 0.430 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2020 | 18 | 0.430 |
Why?
|
| Hypoxia | 2 | 2022 | 649 | 0.430 |
Why?
|
| Pediatrics | 2 | 2021 | 350 | 0.420 |
Why?
|
| Radiotherapy | 1 | 2014 | 331 | 0.420 |
Why?
|
| Young Adult | 17 | 2024 | 6151 | 0.410 |
Why?
|
| Cancer Survivors | 2 | 2024 | 92 | 0.400 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2020 | 71 | 0.400 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 182 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 610 | 0.400 |
Why?
|
| Treatment Outcome | 14 | 2022 | 8104 | 0.400 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2395 | 0.400 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 66 | 0.390 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 11 | 0.390 |
Why?
|
| Age Factors | 11 | 2021 | 1853 | 0.380 |
Why?
|
| Algorithms | 1 | 2019 | 1857 | 0.380 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 195 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 858 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2023 | 4247 | 0.380 |
Why?
|
| Quinoxalines | 1 | 2011 | 50 | 0.370 |
Why?
|
| Iodine Radioisotopes | 4 | 2022 | 134 | 0.370 |
Why?
|
| Pyridines | 2 | 2012 | 313 | 0.370 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 1094 | 0.360 |
Why?
|
| Parents | 3 | 2023 | 281 | 0.350 |
Why?
|
| Palliative Care | 2 | 2023 | 263 | 0.350 |
Why?
|
| Proportional Hazards Models | 8 | 2024 | 856 | 0.340 |
Why?
|
| Recurrence | 5 | 2023 | 1168 | 0.340 |
Why?
|
| Databases, Factual | 4 | 2024 | 839 | 0.340 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 313 | 0.340 |
Why?
|
| International Cooperation | 3 | 2020 | 123 | 0.330 |
Why?
|
| Biomedical Research | 3 | 2021 | 385 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 599 | 0.320 |
Why?
|
| Health Status Disparities | 1 | 2010 | 175 | 0.320 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 900 | 0.310 |
Why?
|
| Adult | 23 | 2024 | 26131 | 0.300 |
Why?
|
| Survivors | 3 | 2022 | 234 | 0.290 |
Why?
|
| United States | 7 | 2024 | 6809 | 0.280 |
Why?
|
| Ganglioneuroblastoma | 2 | 2018 | 4 | 0.270 |
Why?
|
| Risk | 4 | 2019 | 660 | 0.260 |
Why?
|
| Mice | 6 | 2024 | 11619 | 0.260 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1414 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 655 | 0.250 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2022 | 112 | 0.250 |
Why?
|
| Health Information Interoperability | 1 | 2024 | 2 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2020 | 106 | 0.240 |
Why?
|
| Mixed Function Oxygenases | 2 | 2022 | 68 | 0.240 |
Why?
|
| Survival Analysis | 7 | 2021 | 1539 | 0.230 |
Why?
|
| Gangliosides | 2 | 2016 | 10 | 0.230 |
Why?
|
| Thoracic Neoplasms | 2 | 2014 | 64 | 0.230 |
Why?
|
| Radionuclide Imaging | 3 | 2021 | 221 | 0.230 |
Why?
|
| Genome-Wide Association Study | 3 | 2017 | 1659 | 0.230 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 340 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 156 | 0.230 |
Why?
|
| Gene Frequency | 2 | 2017 | 682 | 0.220 |
Why?
|
| Disease Progression | 5 | 2014 | 1479 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 110 | 0.220 |
Why?
|
| Incidence | 5 | 2024 | 1580 | 0.220 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 27 | 0.220 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 64 | 0.220 |
Why?
|
| Lymph Nodes | 2 | 2019 | 546 | 0.220 |
Why?
|
| Watchful Waiting | 2 | 2013 | 61 | 0.210 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 331 | 0.210 |
Why?
|
| Ferritins | 2 | 2020 | 29 | 0.210 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 170 | 0.210 |
Why?
|
| Time Factors | 6 | 2019 | 5284 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 100 | 0.210 |
Why?
|
| Brain Neoplasms | 3 | 2014 | 773 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.210 |
Why?
|
| Central Nervous System | 1 | 2023 | 152 | 0.200 |
Why?
|
| Transcriptome | 2 | 2016 | 613 | 0.200 |
Why?
|
| Adenosine | 1 | 2024 | 237 | 0.190 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 172 | 0.190 |
Why?
|
| Neoplasms | 3 | 2021 | 2984 | 0.190 |
Why?
|
| Nomograms | 1 | 2020 | 29 | 0.190 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2023 | 8780 | 0.190 |
Why?
|
| Genotype | 2 | 2017 | 1866 | 0.180 |
Why?
|
| Research Report | 3 | 2021 | 43 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.180 |
Why?
|
| Animals | 6 | 2024 | 27028 | 0.180 |
Why?
|
| Rituximab | 1 | 2020 | 119 | 0.180 |
Why?
|
| Attitude to Death | 1 | 2019 | 36 | 0.170 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 36 | 0.170 |
Why?
|
| Mitotic Index | 2 | 2020 | 20 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 31 | 0.170 |
Why?
|
| Drug Interactions | 1 | 2019 | 248 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2011 | 506 | 0.170 |
Why?
|
| Cell Movement | 3 | 2022 | 780 | 0.170 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1141 | 0.170 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 9 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 172 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2009 | 74 | 0.170 |
Why?
|
| Social Stigma | 1 | 2019 | 60 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 266 | 0.160 |
Why?
|
| Mitosis | 2 | 2020 | 152 | 0.160 |
Why?
|
| Heterografts | 1 | 2019 | 102 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 138 | 0.160 |
Why?
|
| Lymphoma | 1 | 2019 | 264 | 0.160 |
Why?
|
| Receptors, KIR | 1 | 2017 | 9 | 0.150 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.150 |
Why?
|
| Ataxia | 1 | 2017 | 39 | 0.150 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 447 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 267 | 0.150 |
Why?
|
| Neurologic Examination | 1 | 2017 | 119 | 0.150 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 50 | 0.150 |
Why?
|
| Nurse's Role | 1 | 2017 | 12 | 0.150 |
Why?
|
| Age of Onset | 2 | 2015 | 311 | 0.150 |
Why?
|
| Biomarkers | 3 | 2020 | 1744 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 268 | 0.140 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 67 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 252 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 539 | 0.140 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 76 | 0.140 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 129 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2017 | 287 | 0.140 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.140 |
Why?
|
| Mutation | 3 | 2016 | 4078 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 78 | 0.130 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.130 |
Why?
|
| Melphalan | 1 | 2016 | 98 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 994 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1697 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2017 | 133 | 0.130 |
Why?
|
| Thiamine | 1 | 2015 | 8 | 0.130 |
Why?
|
| Wernicke Encephalopathy | 1 | 2015 | 6 | 0.130 |
Why?
|
| Melanoma | 1 | 2019 | 462 | 0.130 |
Why?
|
| Genes, myc | 1 | 2015 | 39 | 0.130 |
Why?
|
| Autografts | 4 | 2017 | 28 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 498 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 332 | 0.130 |
Why?
|
| Apoptosis | 2 | 2019 | 1705 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 50 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 353 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 990 | 0.120 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 294 | 0.120 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 19 | 0.120 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 96 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 237 | 0.120 |
Why?
|
| Karyotyping | 1 | 2014 | 253 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2012 | 175 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2016 | 354 | 0.120 |
Why?
|
| Cell Survival | 1 | 2016 | 977 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 179 | 0.120 |
Why?
|
| Dacarbazine | 2 | 2013 | 102 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2015 | 160 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 951 | 0.120 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 17 | 0.120 |
Why?
|
| Patient Selection | 2 | 2015 | 685 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 24 | 0.120 |
Why?
|
| SEER Program | 1 | 2014 | 196 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2012 | 148 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 39 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2740 | 0.120 |
Why?
|
| Immunomagnetic Separation | 1 | 2013 | 8 | 0.120 |
Why?
|
| Camptothecin | 2 | 2013 | 190 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2012 | 682 | 0.120 |
Why?
|
| Cell Nucleolus | 1 | 2013 | 24 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 44 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 681 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2018 | 370 | 0.110 |
Why?
|
| Computational Biology | 1 | 2016 | 536 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2012 | 810 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 102 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1843 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 467 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 126 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 60 | 0.100 |
Why?
|
| Fenretinide | 1 | 2011 | 2 | 0.100 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2011 | 34 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 131 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1827 | 0.100 |
Why?
|
| Topotecan | 1 | 2011 | 45 | 0.100 |
Why?
|
| Drug Monitoring | 3 | 2018 | 117 | 0.100 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2011 | 27 | 0.100 |
Why?
|
| Niacinamide | 1 | 2011 | 114 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 834 | 0.100 |
Why?
|
| Loss of Heterozygosity | 3 | 2018 | 86 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 317 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 113 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 396 | 0.100 |
Why?
|
| Radiopharmaceuticals | 3 | 2018 | 190 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2013 | 335 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 572 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2008 | 66 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 372 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 779 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 262 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 295 | 0.090 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 69 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 300 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1759 | 0.090 |
Why?
|
| Pregnancy Rate | 1 | 2009 | 20 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 364 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1786 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1224 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 72 | 0.070 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 186 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 1057 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 126 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 202 | 0.070 |
Why?
|
| Communication | 2 | 2020 | 448 | 0.070 |
Why?
|
| Consensus | 2 | 2018 | 349 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 366 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 197 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2018 | 297 | 0.060 |
Why?
|
| Carboplatin | 2 | 2018 | 302 | 0.060 |
Why?
|
| Viral Load | 2 | 2019 | 152 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2574 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1100 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1037 | 0.060 |
Why?
|
| Goals | 1 | 2023 | 64 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2014 | 288 | 0.060 |
Why?
|
| Capsules | 2 | 2013 | 38 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 147 | 0.050 |
Why?
|
| Vincristine | 1 | 2021 | 112 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 555 | 0.050 |
Why?
|
| Diploidy | 1 | 2020 | 31 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2014 | 726 | 0.040 |
Why?
|
| Therapies, Investigational | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2321 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2003 | 513 | 0.040 |
Why?
|
| Alabama | 1 | 2019 | 11 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
|
| Decision Making | 2 | 2019 | 655 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2013 | 861 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 495 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2018 | 15 | 0.040 |
Why?
|
| Filgrastim | 1 | 2018 | 57 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1020 | 0.040 |
Why?
|
| Azepines | 1 | 2018 | 23 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 593 | 0.040 |
Why?
|
| Quality of Life | 2 | 2019 | 1638 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 108 | 0.040 |
Why?
|
| Ecosystem | 1 | 2021 | 336 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 794 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 927 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 39 | 0.040 |
Why?
|
| Thymus Hyperplasia | 1 | 2016 | 3 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 294 | 0.040 |
Why?
|
| Pregnancy | 3 | 2009 | 2974 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 148 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 139 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 437 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 108 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 348 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 303 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 147 | 0.030 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2624 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 575 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 126 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2008 | 333 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1397 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 359 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Suspensions | 1 | 2013 | 6 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 617 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 63 | 0.030 |
Why?
|
| Middle Aged | 3 | 2019 | 25477 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 297 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 34 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 116 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 360 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 78 | 0.030 |
Why?
|
| Cytosine | 1 | 2014 | 128 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 306 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3425 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 154 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 281 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 322 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 157 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2012 | 46 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2012 | 110 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 96 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 147 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 341 | 0.030 |
Why?
|
| Ploidies | 1 | 2011 | 41 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 570 | 0.030 |
Why?
|
| Tretinoin | 1 | 2012 | 127 | 0.030 |
Why?
|
| Thymopentin | 1 | 2011 | 2 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 20 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1939 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 266 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 272 | 0.020 |
Why?
|
| Research | 1 | 2012 | 250 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 353 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1996 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2010 | 66 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 175 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 102 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1181 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 96 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 475 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 200 | 0.020 |
Why?
|
| North America | 1 | 2010 | 184 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 303 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 18750 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 313 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 680 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 761 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 513 | 0.020 |
Why?
|
| Gravidity | 1 | 2009 | 7 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 907 | 0.020 |
Why?
|
| Sex Education | 1 | 2009 | 10 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2009 | 48 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 63 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2009 | 31 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6655 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 795 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 27 | 0.020 |
Why?
|
| Birth Weight | 1 | 2008 | 145 | 0.020 |
Why?
|
| Body Height | 1 | 2008 | 100 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1563 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 57 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 2424 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2007 | 92 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 941 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1366 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 476 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 231 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 165 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 252 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 520 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2317 | 0.010 |
Why?
|
| Hepatitis A Vaccines | 1 | 2003 | 3 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 2003 | 3 | 0.010 |
Why?
|
| Mumps virus | 1 | 2003 | 3 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 2003 | 10 | 0.010 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2003 | 5 | 0.010 |
Why?
|
| Azithromycin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2003 | 99 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 80 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 3331 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 765 | 0.010 |
Why?
|